Ultragenyx Pharmaceutical offers 145% upside with 20% annual growth from Crysvita and key H2 2025 pipeline data. Check out why RARE stock is a buy.

Ionis is hoping to gain approval of Trygolza in severe hypertriglyceridemia which could set to to generate $2bn in sales.

Scientists from UC Davis Center for Surgical Bioengineering, the MIND Institute and UC Berkeley’s Murthy Lab are developing ...

An 80-year-old artist, her two sons and her daughter-in-law have been found dead in a suspected triple murder-suicide that ...

Neuroscientists and philosophers have debated this thought experiment for decades as they have tried to understand how the ...

Positive interim efficacy data in 2025 underscore potential of ETX101 as a one-time, disease-modifying medicine for Dravet syndrome –– Internal GMP manufacturing capable of supporting pivotal trial ...

Consciousness researchers studying “islands of awareness” have found that disconnected brains likely sink into a strange form ...

The Pinball Lounge at 78th Street Sudios offers an ideal setting for this unique fundraiser. The event runs from 4-6 pm, providing families with an accessible Sunday afternoon activity. True to its ...

Years after the first reports of Havana Syndrome emerged, U.S. officials have obtained and are testing a device​ that could ...

This reported machine may be linked to “Havana syndrome,” a debated condition characterized by a strange panoply of symptoms ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced highlights from the Company's 2025 achievements and provided ...

A baby was born with a syndrome so rare it doesn’t have a name – after doctors spotted his “beautiful” wide eyes. Oska-Gray Valentine-Colquhoun, 20 months old, spent his first days in the NICU after ...